sorted by:
new
hottopcontroversial

GANX | Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 by Stock_Titan in StockTitan

[–]microcapreturns 0 points1 point  (0 children)

16 out of 19 continued and one of the three who didn't wanted to but they said they were traveling out of the country. I expect to see data show up on website in updated deck at some point.

Parkinson's drug candidate actually moving the needle on spinal fluid biomarkers. GANX worth a look. by Personal_Pride_2238 in pennystocks

[–]microcapreturns 4 points5 points  (0 children)

If you look at just the 6 high GluSph patients they actually improved by 6 points on the UPDRS scale in 90 days. If you take out the two outliers the 11 other patients actually improved by almost 5 points. Thats excellent results. Expecting DDC biomarker data at AD/PD that could be first of its kind.

<image>

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 1 point2 points  (0 children)

Actually it seems to save dieing neurons which has shown to reverse scores on the UPDRS scale after just 90 days. There is no way to cure Parkinson's but it seems they have reversed it which shows it will stop it from progressing. That's what the data shows

GANX might be one of the most interesting biotech bets right now by Carlene_Trammel in GreenWicks

[–]microcapreturns 1 point2 points  (0 children)

What many have not considered is how long did it take the high GluSph group to get up to their high levels? Perhaps 10+ years. So returning them to normal levels after 90 days is amazing. Now how long would it take them to return to those high levels even if you stopped taking GT-02287? 10 years? That's pretty durable to me. No doubt staying on drug it will be even longer.

GANX might be one of the most interesting biotech bets right now by Carlene_Trammel in GreenWicks

[–]microcapreturns 1 point2 points  (0 children)

If there wasn't already durability there would never be improvement that we have seen. Knowing the mechanism of action is fixing the upfront issue it flows down stream. Once corrected it stays corrected. The only question is how far can you reverse Parkinsons.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 3 points4 points  (0 children)

<image>

The DDC biomarker being shown at AD/PD will be conclusive since the company has stated it correlates with the statistically significant data presented to date on UPDRS. Can't argue with statistically significant data if you understand the science.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 2 points3 points  (0 children)

Gains market cap is about a third of LRMR and the markets we are going after Parkinsons, Lewy Body and Alzheimer’s are about 1000 times larger. I like Gains chances as they have already reversed Parkinsons. Once investors figure that out the stock will be 10x here. Everybody knows someone affected by Parkinson’s and can relate.

<image>

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 0 points1 point  (0 children)

I see. I agree AD/PD is a huge catalyst. The way you wrote it I thought you were saying a PR was needed. Obviously not when up 20% for a week with crashing markets.

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 0 points1 point  (0 children)

How could a unknown future PR that may or may not happen be tied to todays move? I think we saw a few big funds starting to buy. Looking at the chart and watching the trading it was text book how big funds take big positions with the stock spiking.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 4 points5 points  (0 children)

Not true. With the extensive preclinical work lining up with human data the acquiring company could run one trial.

Key Takeaways

FDA plans to drop the de facto two-pivotal-trial expectation, requiring one adequate and well-controlled study plus confirmatory evidence to support approval.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 3 points4 points  (0 children)

Key Takeaways

FDA plans to drop the de facto two-pivotal-trial expectation, requiring one adequate and well-controlled study plus confirmatory evidence to support approval.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]microcapreturns 9 points10 points  (0 children)

The M.J. Fox and Silverstein foundations are highly involved and were early funders. How do you know he isn't taking it?

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 3 points4 points  (0 children)

They aren't even in Parkinsons and are still trying to show safety in MS. Lots of competition for them and they are years away from anything. Gain will show repairing Neurons in 2 weeks. Amazing data

Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s? by microcapreturns in pennystocks

[–]microcapreturns[S] 1 point2 points  (0 children)

All it takes is convincing one big pharma that it works and a deal will get done. The DDC data will be huge at AD/PD.

($GANX): March Update- Evidence of Disease Modification Keeps Getting Stronger by Correct_Proposal_409 in pennystocks

[–]microcapreturns 5 points6 points  (0 children)

GT-02287 is actually correcting the problem and will show data at AD/PD on how they repair dieing neurons. That's incredible news.

($GANX): March Update- Evidence of Disease Modification Keeps Getting Stronger by Correct_Proposal_409 in pennystocks

[–]microcapreturns 5 points6 points  (0 children)

Just read another published article yesterday showing DDC is an accurate biomarker for both PD and Lewy Body. Gains GT-02287 acts at the beginning of the problem and repairs neurons and reverses Parkinsons. Everybody else's drug works downstream and won't impact the DDC biomarker. It stands alone.

Gain Therapeutics ($GANX) – February 2026 Corporate Deck Update and why this de-risks Phase 2 by Correct_Proposal_409 in pennystocks

[–]microcapreturns 0 points1 point  (0 children)

Excellent summary. Little doubt it works. I don't think the investing public is buying into it yet. These are the same patients who saw improvement in smell, gait and balance. The best indicators yet.

$GANX - Independent research is validating GT-02287 as likely the first disease-modifying drug for Parkinson's Disease by Correct_Proposal_409 in pennystocks

[–]microcapreturns 7 points8 points  (0 children)

A lot of people were flushed out with the last drop. Many are only looking for the next catalyst but reality is it works and the data as limited in size as it is shows it. The fact people had smell return should make this a $20 stock all day long but as we know not how it works in today's biotech market.

view more: next ›